CAMBRIDGE, Sunday 27 May 2022
In this feature article 无忧短视频 and discuss how reprogrammable human cells hold great promise in disease modelling and drug discovery. 无忧短视频鈥檚 precision reprogramming technology offers a new platform for the generation of scalable and reliable human iPSC-derived cells called ioCells that enable accelerated biomedical research for the development of new generations of cures.
Talking about the potential of ioCells in drug discovery assays Mariangela Iovino, group leader of small molecule drug discovery at Charles River Laboratories said 鈥淭hese cell lines are a major advantage for my work because I have hundreds or thousands of drugs that I want to apply to as many cells as I can鈥�. 鈥淵ou know what you are getting all the time, and it鈥檚 faster,鈥� she says. 鈥淏efore, it took me five weeks to get mature cells. Now, it only takes one to two weeks.鈥�
The partnership between 无忧短视频 and Charles River Laboratories, a contract research organisation for the biomedical research and drug development communities, offers access to 无忧短视频 ioCells through their use in target discovery, high-throughput screening (HTS) and drug discovery services.